EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

A guide to reverse metabolomics—a framework for big data discovery strategy

Vincent Charron-Lamoureux, Helena Mannochio-Russo, Santosh Lamichhane, Shipei Xing iD, Abubaker Patan iD, Paulo Wender Portal Gomes, Prajit Rajkumar iD, Victoria Deleray, Andrés Mauricio Caraballo-Rodríguez, Kee Voon Chua iD, Lye Siang Lee iD, Zhao Liu und 3 weitere

Nature Protocols · 2025

DOI: 10.1038/s41596-024-01136-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Protocols, 2025. Verfasst von Vincent Charron-Lamoureux und 14 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jol…. Hauptthemen laut MEDLINE: Metabolomics, Big Data, Data Mining. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Health & Human Services | National Institutes of Health (NIH), Gordon and Betty Moore Foundation (Gordon E. and Betty I. Moore Foundation), U.S. Department of Energy (DOE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Untargeted metabolomics is evolving into a field of big data science. There is a growing interest within the metabolomics community in mining tandem mass spectrometry (MS/MS)-based data from public repositories. In traditional untargeted metabolomics, samples to address a predefined question are collected and liquid chromatography with MS/MS data are generated. We then identify metabolites associated with a phenotype (for example, disease versus healthy) and elucidate or validate their structural details (for example, molecular formula, structural classification, substructure or complete structural annotation or identification). In reverse metabolomics, we start with MS/MS spectra for known or unknown molecules. These spectra are used as search terms to search public data repositories to discover phenotype-relevant information such as organ/biofluid distribution, disease condition, intervention status (for example, pre- and postintervention), organisms (for example, mammals versus others), geography and any other biologically relevant associations. Here we guide the reader through a four-part process: (1) obtaining the MS/MS spectra of interest (Universal Spectrum Identifier) and (2) Mass Spectrometry Search Tool searches to find the files associated with the MS/MS that are in available databases, (3) using the Reanalysis Data User Interface framework to link the files with their metadata and (4) validating the observations. Parts 1-3 could take from hours to days depending on the method used for collecting MS/MS spectra. For example, we use MS/MS spectra from three small molecules: phenylalanine-cholic acid (a microbially conjugated bile acid), phenylalanine-C4:0 and histidine-C4:0 (two N-acyl amides). We leverage the Global Natural Products Social Molecular Networking-based framework to explore the microbial producers of these molecules and their associations with health conditions and organ distributions in humans and rodents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetabolomicsBig DataData MiningTandem Mass SpectrometryHumansAnimalsChromatography, LiquidDatabases, Factual

Autor:innen und Institutionen

  • Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
  • Turku Bioscience Center, University of Turku and Åbo Akademi University, Turku, Finland.
  • Cardiovascular and Metabolic Disorders Programme, Duke-NUS Medical School, Singapore, Singapore.
  • KK research Centre, KK Women's and Children's Hospital, Singapore, Singapore.
  • Department of Computer Science, University of California Riverside, Riverside, CA, USA.

ORCID-Profile: Shipei Xing, Abubaker Patan, Prajit Rajkumar, Kee Voon Chua, Lye Siang Lee, Mingxun Wang, Pieter C Dorrestein

Förderung

  • U.S. Department of Health & Human Services | National Institutes of Health (NIH)
  • Gordon and Betty Moore Foundation (Gordon E. and Betty I. Moore Foundation)
  • U.S. Department of Energy (DOE)
  • Fonds de Recherche du Québec - Santé (Fonds de la recherche en sante du Quebec)
  • NIDDK NIH HHS

Zitieren

APA

Charron-Lamoureux, V., Mannochio-Russo, H., Lamichhane, S., Xing, S., Patan, A., Portal Gomes, P. W., Rajkumar, P., Deleray, V., Caraballo-Rodríguez, A. M., Chua, K. V., Lee, L. S., Liu, Z., Ching, J., Wang, M., & Dorrestein, P. C. (2025). A guide to reverse metabolomics—a framework for big data discovery strategy. Nature Protocols. https://doi.org/10.1038/s41596-024-01136-2

Vancouver

Charron-Lamoureux V, Mannochio-Russo H, Lamichhane S, Xing S, Patan A, Portal Gomes PW, et al. A guide to reverse metabolomics—a framework for big data discovery strategy. Nature Protocols. 2025. doi:10.1038/s41596-024-01136-2

BibTeX
@article{CharronLamoureux2025,
  author = {Charron-Lamoureux, Vincent and Mannochio-Russo, Helena and Lamichhane, Santosh and Xing, Shipei and Patan, Abubaker and Portal Gomes, Paulo Wender and Rajkumar, Prajit and Deleray, Victoria and Caraballo-Rodríguez, Andrés Mauricio and Chua, Kee Voon and Lee, Lye Siang and Liu, Zhao and Ching, Jianhong and Wang, Mingxun and Dorrestein, Pieter C},
  title = {A guide to reverse metabolomics—a framework for big data discovery strategy},
  journal = {Nature Protocols},
  year = {2025},
  doi = {10.1038/s41596-024-01136-2}
}
Kostenlos starten →